BMO Capital Downgrades Amgen to Hold Rating with Target Price at $450

BMO Capital analyst Evan Seigerman has downgraded Amgen (AMGN.US) to a hold rating, while maintaining the target price at $450. This decision is based on the analyst's past performance, which includes a success rate of 59.9% and an average return of 11.4% over the past year.

TipRanks provides data on financial analysts' recommendations, including their success rates and average returns. According to this data, Evan Seigerman has a 5-star rating, indicating his strong performance in making accurate predictions. However, it's worth noting that past performance is not always indicative of future results.